eukaryotic translation initiation factor 4E binding protein 2 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored EIF4EBP2P2 profile across patient tissues and cancer cell-line models. EIF4EBP2P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EIF4EBP2P2 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, EIF4EBP2P2 RNA expression shows 9,729 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRP, STAD, and LAML as cancer lineages where EIF4EBP2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4EBP2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4EBP2P2 survival associations across molecular data types. EIF4EBP2P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4EBP2P2 RNA expression–survival associations across cancer types. High EIF4EBP2P2 expression shows unfavorable associations in KIRP, BRCA, DLBC and KICH, but favorable associations in OV and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EIF4EBP2P2 RNA expression.
This table summarizes EIF4EBP2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4EBP2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4EBP2P2 shows lower tumor expression in STAD. The STAD box plot shows higher EIF4EBP2P2 RNA expression in normal versus tumor tissue (log2 FC = −0.241, t-test p = .011).
This table shows molecular features associated with EIF4EBP2P2 in patient tissues and cancer cell lines. In patient samples, EIF4EBP2P2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
